Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
July 25 2022 - 8:30AM
Business Wire
- Oral presentation will take place on Monday,
September 12 at 5:25 pm Central European Summer Time (CEST)
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, today announced
that data from the company’s Phase 1 study of zanidatamab zovodotin
(ZW49), an investigational novel bispecific HER2 targeted
antibody-drug conjugate, were accepted for an oral presentation at
the European Society for Medical Oncology Congress 2022 in
Paris.
The abstract, entitled “Preliminary
Results From a Phase 1 Study Using the Bispecific, Human Epidermal
Growth Factor 2 (HER2)-targeting Antibody-drug Conjugate (ADC)
zanidatamab zovodotin (ZW49) in Solid Cancers”, will be
presented by Komal Jhaveri, M.D., Medical Oncologist, Memorial
Sloan Kettering Cancer Center in NYC, in a mini-oral presentation
on Monday, September 12 at 5:25 pm CEST during the ESMO meeting
being held September 9-13, 2022, at the Paris Expo Porte de
Versailles in Paris, France.
“This presentation represents an important milestone for
Zymeworks as the first opportunity to share clinical data from our
zanidatamab zovodotin development program,” said Kenneth Galbraith,
Chair and CEO of Zymeworks. “We are especially pleased to present
these data at ESMO, which provides us an opportunity to update many
of the global leaders in cancer research from around the world on
this important effort.”
Zymeworks will host a conference call to further discuss the
clinical data presented at ESMO and provide an overview on future
clinical development plans for zanidatamab zovodotin after the
presentation.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the discovery, development and commercialization of
next-generation multifunctional biotherapeutics. Zymeworks’ suite
of therapeutic platforms and its fully integrated drug development
engine enable precise engineering of highly differentiated product
candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a
novel Azymetric™ HER2-targeted bispecific antibody currently being
evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials
globally as a targeted treatment option for patients with solid
tumors that express HER2. Zymeworks’ second clinical candidate,
zanidatamab zovodotin (ZW49), is a novel bispecific HER2 ‑targeted
antibody-drug conjugate currently in Phase 1 clinical development
and combines the unique design and antibody framework of
zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and
cytotoxin. Zymeworks is also advancing a deep preclinical pipeline
in oncology (including immuno-oncology agents) and other
therapeutic areas. In addition, its therapeutic platforms are being
leveraged through strategic partnerships with global
biopharmaceutical companies. For more information on our ongoing
clinical trials visit www.zymeworksclinicaltrials.com. For
additional information about Zymeworks, visit www.zymeworks.com and
follow @ZymeworksInc on Twitter.
Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and “forward-looking information” within the meaning of
Canadian securities laws, or collectively, forward-looking
statements. Forward-looking statements in this press release
include, but are not limited to, statements that relate to the
potential therapeutic effects of zanidatamab, zanidatamab zovodotin
and Zymeworks’ other product candidates; Zymeworks’ clinical
development of its product candidates; anticipated clinical data
presentations; and other information that is not historical
information. When used herein, words such as “will”, “plans”,
“may”, “potential”, and similar expressions are intended to
identify forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Zymeworks’ current expectations and various
assumptions. Zymeworks believes there is a reasonable basis for its
expectations and beliefs, but they are inherently uncertain.
Zymeworks may not realize its expectations, and its beliefs may not
prove correct. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various factors, including, without limitation: the impact of
the COVID-19 pandemic on Zymeworks’ business, research and clinical
development plans and timelines and results of operations,
including impact on its clinical trial sites, collaborators, and
contractors who act for or on Zymeworks’ behalf, may be more severe
and more prolonged than currently anticipated; clinical trials may
not demonstrate safety and efficacy of any of Zymeworks’ or its
collaborators’ product candidates; any of Zymeworks’ or its
partners’ product candidates may fail in development, may not
receive required regulatory approvals, or may be delayed to a point
where they are not commercially viable; regulatory agencies may
impose additional requirements or delay the initiation of clinical
trials; the impact of new or changing laws and regulations; and the
factors described under “Risk Factors” in Zymeworks’ quarterly and
annual reports filed with the Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for its quarter ended
March 31, 2022 (a copy of which may be obtained at www.sec.gov and
www.sedar.com). Consequently, forward-looking statements should be
regarded solely as Zymeworks’ current plans, estimates and beliefs.
Investors should not place undue reliance on forward-looking
statements. Zymeworks cannot guarantee future results, events,
levels of activity, performance or achievements. Zymeworks does not
undertake and specifically declines any obligation to update,
republish, or revise any forward-looking statements to reflect new
information, future events or circumstances or to reflect the
occurrences of unanticipated events, except as may be required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220725005250/en/
Jack Spinks (604) 678-1388 ir@zymeworks.com
Media Inquiries: Diana Papove (604) 678-1388
media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Apr 2023 to Apr 2024